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Resveratrol induces autophagy by 
directly inhibiting mTOR through 
ATP competition
Dohyun Park1, Heeyoon Jeong1, Mi Nam Lee1, Ara Koh1, Ohman Kwon2, Yong Ryoul Yang3, 
Jungeun Noh1, Pann-Ghill Suh3, Hwangseo Park4 & Sung Ho Ryu1,2
Resveratrol (RSV) is a natural polyphenol that has a beneficial effect on health, and resveratrol-
induced autophagy has been suggested to be a key process in mediating many beneficial effects of 
resveratrol, such as reduction of inflammation and induction of cancer cell death. Although various 
resveratrol targets have been suggested, the molecule that mediates resveratrol-induced autophagy 
remains unknown. Here, we demonstrate that resveratrol induces autophagy by directly inhibiting the 
mTOR-ULK1 pathway. We found that inhibition of mTOR activity and presence of ULK1 are required 
for autophagy induction by resveratrol. In line with this mTOR dependency, we found that resveratrol 
suppresses the viability of MCF7 cells but not of SW620 cells, which are mTOR inhibitor sensitive and 
insensitive cancer cells, respectively. We also found that resveratrol-induced cancer cell suppression 
occurred ULK1 dependently. For the mechanism of action of resveratrol on mTOR inhibition, we 
demonstrate that resveratrol directly inhibits mTOR. We found that resveratrol inhibits mTOR by 
docking onto the ATP-binding pocket of mTOR (i.e., it competes with ATP). We propose mTOR as a 
novel direct target of resveratrol, and inhibition of mTOR is necessary for autophagy induction.
Resveratrol (3,40,5-trihydroxy-trans-stilbene) is a natural polyphenolic compound found in the roots of plants 
and in edible fruits including berries and grapes. Administration of resveratrol is thought to elicit beneficial 
effects, including alleviation of inflammation and tumor cell death in applied cells and organisms1. Autophagy is 
a cellular process that removes damaged organelles or cellular constituents and provides energy under starvation 
conditions or repairs damage under stressed conditions. The autophagic process is of great interest because of 
its high association with various diseases, including cancer, neurodegenerative diseases, myopathy, and cardiac 
disease. Aberrant regulation of autophagy has been observed in various diseases, and activation of autophagy 
is known to alleviate symptoms and perhaps even cure these diseases2,3. Recently, resveratrol was suggested to 
induce autophagy, and this process is responsible for the beneficial effects of resveratrol, including reduction 
of inflammation, induction of tumor cell death, and protection against oxidative damage4. Several groups have 
attempted to explain the mechanism by which resveratrol induces autophagy and have suggested the mediator of 
this process5–7. Nonetheless, evidence directly linking resveratrol to autophagy is still lacking.
mTOR (the mammalian or mechanistic target of rapamycin), a Ser/Thr kinase present in cells, functions 
within two distinct complexes: mTORC1 (mTOR complex 1) and mTORC2 (mTOR complex 2). These complexes 
share mTOR as a kinase subunit, but contain different adaptors and scaffolds for distinct functions and regulatory 
mechanisms. mTORC1 controls cell growth and proliferation through the regulation of various processes and 
promotes translation through the phosphorylation of S6K and 4E-BP1. Lipid synthesis is also enhanced by active 
mTOR through the regulation of PPAR-γ , SREBP, and Lipin18,9. In addition to these anabolic processes, mTORC1 
also suppresses catabolism by inhibiting autophagy. Inhibition of mTORC1 is sufficient to induce autophagy, and 
nutrient-insensitive mTOR renders cells unresponsive to starvation-induced autophagy10. Active mTOR inhibits 
autophagy by suppressing the ULK1-ATG13-FIP200 complex, specifically through the inhibitory phosphoryl-
ation of ULK111–14. Several studies have shown that resveratrol suppresses mTOR activity, which is expected to 
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mediate resveratrol-induced autophagy. For the mechanism of inhibition, involvement of upstream regulators, 
including PI3K, AMPK, and SIRT1, has been suggested5,15,16. However, conflicting results between these reports 
for the requirement of above-mentioned regulators in resveratrol-induced mTOR suppression result in ambiguity.
Here, we demonstrate that resveratrol induces autophagy through the mTOR-ULK1 pathway. Additionally, 
we found that resveratrol induces death of the cancer cells known to be sensitive to mTOR inhibition in ULK1 
dependent manner. With respect to the mechanism by which resveratrol reduces mTOR activity, we demon-
strated that resveratrol directly inhibits mTOR in an ATP-competitive manner. Through this study we suggest that 
mTOR is a distinct and direct target of resveratrol, and inhibition of mTOR is necessary for resveratrol-induced 
autophagy.
Results
Resveratrol induces autophagy through mTOR inhibition. In order to understand resveratrol-in-
duced autophagy, we examined the effect of resveratrol on autophagy in GFP-LC3 expressing HeLa cells. 
Resveratrol treatment induces autophagy, as evidenced by the accumulation of LC3B-II and LC3 puncta forma-
tion14 (supplementary Fig. S1). Along with this result, treatment with mTOR kinase inhibitor pp242 demonstrated 
that mTORC1 activity is inversely correlated with the level of autophagy (supplementary Fig. S1A). This result 
implicates the possible involvement of mTORC1 in resveratrol-induced autophagy. To test the position of mTOR 
in resveratrol-induced autophagy, we used various drugs that induce autophagy. We found that combinatory 
treatment with resveratrol and PP242 did not show any additive effect (Fig. 1A,B), indicating that resveratrol acts 
via the same pathway as PP242. Decreased cyclic-AMP (cAMP) levels induce autophagy in an mTOR-independ-
ent manner17. Because reduction of cAMP induces autophagy through inhibition of PKA18, we utilized H-89, a 
PKA inhibitor, to induce mTOR-independent autophagy. As expected, treatment with H-89 increased autophagy 
without reduction of mTORC1 activity. Additionally, unlike the resveratrol-PP242 combination, co-treatment 
with H-89 and resveratrol or H-89 and PP242 had an additive effect on the accumulation of LC3B-II (Fig. 1A). 
This result indicates that H-89 induces autophagy through an mTOR-independent pathway, and resveratrol and 
H-89 use different pathways to induce autophagy. Taken together, these combinatory drug treatment experiments 
indicate that resveratrol induces autophagy at the level as same as mTOR inhibition.
ULK1 is required for resveratrol-induced autophagy. mTOR regulates autophagy through inhibitory 
phosphorylation of ULK1 and inhibition of mTOR decreases the inhibitory phosphorylation level of ULK1 and 
increases autophagy13,14. Therefore, to confirm the involvement of mTOR in resveratrol-induced autophagy and 
to examine the ULK1 dependency, we analyzed the level of autophagy induced by resveratrol in the presence 
or absence of ULK1. ULK1 knockdown using shRNA abolished resveratrol-induced autophagy, indicating that 
ULK1 is required for resveratrol-induced autophagy (Fig. 2A,B). However, ULK1 knockdown did not abolish 
autophagy induced by H-89 treatment (Fig. 2C), again confirming that the mTOR-regulated autophagy is inde-
pendent of the cAMP-PKA pathway. Together, we concluded that resveratrol induces autophagy through the 
mTOR-ULK1 pathway, which includes inhibition of mTOR.
Resveratrol reduces viability of mTOR inhibition sensitive cancer cells in ULK1 dependent manner. 
As previous studies showed, resveratrol-induced autophagy suppresses cancer in vitro and in vivo4,6,19. Therefore, 
we examined whether resveratrol-induced suppression of cancer progression occurred through mTOR and inhi-
bition of ULK1. To examine mTOR dependency on resveratrol induced-cancer cell suppression, we utilized two 
different cell lines that were previously reported mTOR inhibition sensitive and insensitive, respectively20. MCF7, 
a breast cancer cell that has constitutive PI3K activation and higher mTOR activity so that it is sensitive to mTOR 
inhibitor, showed very sensitive response to resveratrol treatment (Fig. 3A). However, neither PP242 nor resver-
atrol reduced the viability of Ras transformed colorectal cancer cells, SW620 (Fig. 3B). This result indicates that 
resveratrol effect on cancer cell viability is largely dependent on impact of mTOR, which varies in cancer cell 
types. To examine whether the effect of resveratrol on cellular viability is reflected in intra-cellular signaling, we 
measured mTOR activity in MCF7 and SW620 cells upon resveratrol and PP242 treatment. The basal level of 
mTOR activity and responsiveness to resveratrol and PP242 were significantly lower in SW620 cells compared 
to MCF7 cells, further demonstrating that the modulation of mTOR activity is involved in the physiological 
effects of resveratrol (Fig. 3C). Next, we examined whether ULK1 is involved in resveratrol-induced suppression 
of cancer cell viability. Like knockdown of ULK1 blunted the autophagy induction by resveratrol, reduction of 
viability of MCF7 cells was partially restored by ULK1 knockdown (Fig. 3D). This restoration of viability was 
also observed in PP242 induced cancer cell suppression (Fig. 3D). These cancer cell specific and ULK1 depend-
ent effect of resveratrol further supports the idea that resveratrol-induced cellular behavior alterations occurred 
through mTOR-ULK1 pathway.
mTOR-associated DEPTOR level is not changed by resveratrol. DEPTOR is a negative regulator 
of both mTORC1 and mTORC2. Liu et al. showed that resveratrol increased the interaction affinity between 
mTOR and DEPTOR and suggested that DEPTOR is required for the suppression of mTOR activity upon resver-
atrol treatment21. To examine the involvement of DEPTOR, we conducted a pull-down assay of FLAG-tagged 
mTOR under various conditions, including resveratrol treatment. Rapamycin was used as a positive control for 
chemically-induced complex dissociation. Unexpectedly, in this condition, both the 10 min and 60 min resvera-
trol treatments did not increase the affinity between mTOR and DEPTOR although resveratrol clearly decreased 
mTOR activity. Treatment with rapamycin led to the detachment of Raptor from mTOR (supplementary Fig. S2).
Resveratrol inhibits mTOR kinase activity in cell-free systems. Next, we examined whether resver-
atrol directly suppresses mTOR activity. To address this question, we performed an in vitro kinase assay. We 
observed that resveratrol dose-dependently decreased the phosphorylation level of 4E-BP1 (Fig. 4A). In addition 
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to the experiments with full-length mTOR, we used a recombinant fragment mTOR that some regulatory 
domains are deleted, but still contains the intact kinase domain for a kinase assay. Notably, resveratrol could 
decrease the phosphorylation of S6K, a substrate of mTOR (Fig. 4B), similar to the results of immunoprecipitated 
full-length mTOR (Fig. 4A). Additionally, we found that resveratrol has an IC50 value of ~10 μ M against mTOR 
kinase activity (Fig. 4C). Taken together, resveratrol inhibits mTOR kinase activity in cell-free systems.
Computational simulation of the interaction between mTOR and resveratrol. To assess the mode 
of action for inhibiting the kinase activity of mTOR, we carried out docking simulations of resveratrol in the 
ATP-binding site of mTOR for determining the lowest-energy binding mode of resveratrol (Fig. 5A). Resveratrol 
appears to be stabilized in the binding pocket formed by the Gly loop, hinge region of the ATP-binding site, and 
the interface residues of N- and C-terminal domains. To examine the possibility of allosteric inhibition of mTOR 
by resveratrol, we performed additional docking simulations with extended 3D grid maps that include the whole 
kinase domain. However, no peripheral binding site was found in which resveratrol could be stabilized with 
Figure 1. Resveratrol induces autophagy through mTOR inhibition. (A) Autophagy induction was analyzed 
by measuring accumulation level of LC3-II. Resveratrol (100 μ M), PP242 (1.25 μ M), H-89 (10 μ M), or a 
combination of two different chemicals was administered to HEK293 cells for 4 h. *P < 0.05 n = 3. (B) LC3 
puncta formation induced by resveratrol (50 μ M), PP242 (1.25 μ M), or a combination of these chemicals was 
examined in HeLa cells stably expressing GFP-LC3 for 2 h. Scale bars in fluorescent pictures represent 20 μ m
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negative free energy of binding. It is thus expected that the micromolar-level inhibitory activity of resveratrol 
against mTOR stems from the specific binding in the ATP binding site.
We now address the detailed interactions responsible for stabilization of resveratrol in the ATP-binding 
pocket. The binding mode of resveratrol calculated from docking simulations is shown in Fig. 5B. We observed 
that the terminal phenolic group of resveratrol receives and donates a hydrogen bond from the backbone amidic 
nitrogen to the aminocarbonyl oxygen of V2240, respectively. This hydrogen bond seems to be important for the 
biochemical potency of resveratrol because the formation of hydrogen bonds with same region was also observed 
in the structures of mTOR complex with potent inhibitors22. In the assessed mTOR-resveratrol complex, two 
additional hydrogen bonds are established between the benzene-1,3-diol moiety and the side-chain carboxylate 
groups of E2190 and D2195. On the basis from docking simulations, it can be argued that the inhibitory activity 
of resveratrol can be attributed to the multiple hydrogen bonds.
Resveratrol inhibits mTOR through ATP competition. To verify the simulation results, we performed 
an in vitro kinase assay with various concentrations of ATP. PP242, a kinase inhibitor of mTOR, was used as a pos-
itive control for mTOR inhibition. We found that resveratrol-induced mTOR inhibition was restored by the addi-
tion of ATP (Fig. 5C,D). To clarify whether resveratrol inhibits mTOR through direct interaction, we generated a 
resveratrol-resistant mTOR mutant. Based on the resolved mTOR-ATP structure22 and our computational simu-
lation (Fig. 5A,B), Asp 2195 was deemed to be a resveratrol-binding residue that does not affect the mTOR-ATP 
interaction. Thereafter, we generated an mTOR mutant in which Asp 2195 was substituted with alanine (hereafter, 
Figure 2. ULK1 is required for resveratrol-induced autophagy. (A) Autophagy induction by resveratrol 
(50 μ M, 2 h) in the presence or absence of ULK1. Lenti virus encoding vector or shULK1 was introduced into 
GFP-LC3 expressing HeLa cells. (B) Autophagy induction by resveratrol (50 μ M, 2 h)in the presence or absence 
of ULK1. cDNA encoding vector or shULK1 was transfected into HEK293 cells. Scale bars in fluorescent 
pictures represent 20 μ m. (C) Autophagy induction by H-89 (10 μ M, 2 h) in the presence or absence of ULK1. 
cDNA encoding vector or shULK1 was transfected into HEK293 cells.
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referred to as D2195A) and performed an in vitro kinase assay. As expected, resveratrol inhibited wild-type (WT) 
mTOR but not D2195A mTOR. The basal activity level of the D2195A mutant was lower than that of WT mTOR, 
possibly due to the fact that the mutated residue resides in the kinase domain of the protein. We observed that 
PP242 also inhibited DA mTOR, albeit the inhibitory potency was less than WT mTOR (Fig. 5E). Although Asp 
2195 was suggested as a residue for the interaction between mTOR and PP242, other residues also participate 
the interaction between them and not all residues are shared between PP242 and resveratrol for mTOR binding. 
Figure 3. Resveratrol reduces viability of mTOR inhibition sensitive cancer cells. (A) MCF7 Cells were 
treated with resveratrol (50 or 100 μ M) or PP242 (500 nM) or CCCP (10 μ M) for 48 h followed by cell viability 
measurement by MTT assay. (B) Chemical treatment and viability measurement for SW620 cells were 
conducted same as MCF7 cells. (C) Intra-cellular signaling was examined in MCF7 cells and SW620 cells after 
4 h treatment of resveratrol (50 μ M) or PP242 (500 nM). n = 3. (D) MCF7 cells were infected with lenti virus 
containing vector or shULK1. After 48 h infection chemical treatment was conducted for another 48 h followed 
by viability measurement. The Y-axis of the graph indicates the levels relative to those of untreated negative 
control samples.
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We speculate that other residues but not D2105 may be essential for the PP242 binding to mTOR and that is 
why D2195A mTOR was not completely resistant to PP242. To examine whether the resveratrol resistant mTOR 
blocks the resveratrol-induced autophagy, we measured the autophagy levels upon resveratrol treatment in the 
WT or D2195A mTOR along with Raptor transfected cells. We found that resveratrol induced autophagy in the 
WT mTOR transfected cells, but not in the D2109A mTOR transfected cells (Fig. 5F). Taken together, the results 
from the experiments using resveratrol resistant mTOR suggest that resveratrol induces autophagy by directly 
inhibits mTOR through ATP competition.
Discussion
We demonstrated that mTOR is the direct target of resveratrol. This claim is supported by the observation that 
mTOR activity is inhibited by addition of resveratrol in vitro. Additionally, this study provides a mechanistic 
explanation for the beneficial effects of resveratrol, which is mTOR-dependent autophagy induction and reduc-
tion of cancer cell viability. These findings also increase the possibility of application of resveratrol to maladies 
that are highly associated with active mTOR, such as neurodegenerative diseases and diabetes.
Because of its beneficial effects, many researchers have attempted to identify the molecular target of resver-
atrol. SIRT1, a NAD+-dependent deacetylase, was initially identified as the direct target of resveratrol by in 
vitro screening23. Additionally, other studies showed that the administration of resveratrol to mice and cells 
decreased the acetylation level of SIRT1 targets24. The similarity in the functional outcome of SIRT1 activation 
and resveratrol administration suggested that SIRT1 can be a direct physiological target of resveratrol. However, 
several later studies reported that resveratrol did not activate SIRT1 in in vitro assays when native peptides, not 
fluorophore-tagged peptides (used in the original in vitro assay), were used as substrates. These results suggested 
that SIRT1 may not be the direct target of resveratrol, although resveratrol clearly activates SIRT1 in vivo25–28. 
Resveratrol was reported to activate AMPK (AMP-activated kinase) and additional studies have suggested that 
AMPK activation mediates the beneficial effects of resveratrol administration29–32. Although resveratrol activates 
AMPK, AMPK is unlikely to be a direct target of resveratrol33,34. After a long search for a direct target of resvera-
trol, Park et al. suggested PDEs (phosphodiesterases) as a direct target of resveratrol. In their report, they found 
that resveratrol inhibits PDEs through competition with cAMP (cyclic AMP), a substrate of PDE. They also 
observed that inhibition of PDE is enough to mimic the effects of resveratrol administration in mice, such as 
AMPK activation, SIRT1 inhibition, and enhancement of metabolic features35. Since the above-mentioned mol-
ecules are the known upstream regulators of mTORC1, inhibition of mTOR by resveratrol was thought to be due 
to these upstream regulators. However, we found that mTOR inhibition by resveratrol is independent of AMPK, 
SIRT1, PDE, and PI3K (data not shown).
Figure 4. Resveratrol inhibits mTOR kinase activity in cell-free systems. (A) An in vitro mTOR kinase 
assay was performed with purified mTOR from HEK293 cells. HA-tagged mTOR was introduced into cells 
and immunoprecipitated with the anti-HA antibody. (B) An in vitro mTOR kinase assay was performed using 
GST-tagged recombinant mTOR. (C) Inhibition curve of mTOR activity with the indicated concentration of 
resveratrol. An in vitro kinase assay was performed as in B. n = 3.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:21772 | DOI: 10.1038/srep21772
Figure 5. Resveratrol inhibits mTOR through ATP competition. (A) Docking pose of resveratrol in the ATP-
binding site of mTOR. (B) Detailed binding mode of resveratrol in the ATP-binding site of mTOR. The carbon 
atoms of resveratrol and mTOR are shown in green and cyan, respectively. Hydrogen bonds are indicated with 
dotted lines. (C) Suppression of activity by resveratrol was dependent on the level of ATP. An in vitro kinase 
assay was performed with the indicated amounts of ATP and resveratrol. mTOR kinase inhibitor PP242 was 
used as a positive control. (D) In vitro kinase was performed with increased amount of ATP. (E) In vitro kinase 
was performed with WT mTOR and D2195A mTOR *P < 0.05 n = 3. (F) WT mTOR or D2195A mTOR, 
and HA-Raptor were transfected into HEK293T cells. After 24 h post transfection, Resveratrol (50 μ M) was 
administered to HEK293 cells for 4 h to measure the accumulation of LC3B-II. *P < 0.05 n = 3.
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Resveratrol was initially identified as a SIRT1 activator because of its structural similarity to quercetin23. 
Considering that quercetin is known to inhibit a broad spectrum of kinases in an ATP-competitive manner and 
that resveratrol also inhibits several kinases36, increased the possibility of ATP competitive mode of action of 
resveratrol in mTOR inhibition. To test the possibility that resveratrol directly binds in the ATP-binding site 
of mTOR, we carried out docking simulations between mTOR and resveratrol (Fig. 5). Detailed binding mode 
analysis of resveratrol implied that its binding in the ATP-binding site of mTOR could be facilitated by the estab-
lishment of multiple hydrogen bonds with the backbone amide groups in the hinge region and the side chains 
of E2190 and D2195. Simultaneously, hydrophobic interactions with the nonpolar residues in the ATP-binding 
pocket were also found to be a significant binding force that stabilizes the mTOR-resveratrol complex. These 
computational results may serve as persuasive evidence for competitive inhibition of mTOR by resveratrol. An 
analysis of mTOR activity using a putative resveratrol binding-defective mutant verified this result by showing 
that resveratrol suppressed WT mTOR but not D2195A mTOR (Fig. 5E). The Asp 2195 residue is also involved in 
mTOR-PP242 binding22. However, PP242 inhibited the D2195A mutant, though its potency was reduced com-
pared to WT mTOR. This result indicates that Asp 2195 is a key residue for mTOR-resveratrol binding.
Resveratrol was reported to directly inhibit various enzymes as demonstrated by in vitro activity assays. 
Among these enzymes, PI3K and PKC showed ATP-dependent inhibition by resveratrol37,38. However, the 
studies provided no evidence for the link between the inhibition of these molecules and the beneficial effects 
of resveratrol administration. Further studies are needed to determine the position of physiological targets of 
resveratrol. In addition to kinases, PDE, which uses cAMP as a substrate, is also inhibited by resveratrol in a 
substrate-competitive manner. Notably, mTOR had the lowest IC50 value for resveratrol compared to PI3K, PKC, 
and PDE. Resveratrol, ATP, and cAMP are similar in structure, which suggested that resveratrol could compete 
with cAMP or ATP for single binding sites. Additionally, PP242 and quercetin, an mTOR kinase inhibitor and a 
natural polyphenol, respectively, are similar in structure.
We found that resveratrol showed a cancer-cell-type-selective effect on viability in that it suppressed only 
the viability of MC7 cells, but not that of SW620 cells (Fig. 3). However, we could not find any differences in the 
level of apoptosis between MCF7 and SW620 cells, which may indicate the involvement of other cellular pro-
cesses. Notably, Colin et al. suggested acquired resistance to resveratrol in SW620 cells, which is dependent on the 
DNA-damage response39. Therefore, it remains to be determined whether mTOR and the DNA-damage response 
are associated with the determination of resveratrol resistance in SW620 cells.
Liu et al. showed that resveratrol suppresses mTOR activity by enhancing the affinity between mTOR and 
DEPTOR, a negative regulator of mTOR. However, we observed no changes in the level of mTOR-interacting 
DEPTOR (supplementary Fig. S2). This discrepancy may be explained by the differences in experimental 
conditions. They used a pull-down assay of endogenous mTOR from C2C12, while we immunoprecipitated 
FLAG-mTOR from HEK293 cells. Additionally, active mTOR was reported to promote the degradation of 
DEPTOR12. Thus, the increase in DEPTOR affinity may be due to the increased level of total DEPTOR pro-
teins within cells due to resveratrol. Altogether, our study suggests that mTOR is a high-affinity direct target of 
resveratrol.
Resveratrol induces autophagy in various cell lines and in model organisms, such as Caenorhabditis elegans 
and mice5–7. In these reports, authors showed that autophagy induction is necessary for cancer cell death and 
alleviation of inflammation, and it may even extend the lifespan. Some studies showed decreased mTOR activity 
along with autophagy induction with resveratrol treatment, but there is no direct evidence suggesting that mTOR 
is a mediator of autophagy induction by resveratrol5,15,16,40. In this study, using a combinatory chemical treat-
ment and ULK1 knockdown, we clearly demonstrated that the mTOR-ULK1 pathway is necessary for autophagy 
induction by resveratrol. In addition to resveratrol, other natural polyphenols, including quercetin and rottlerin 
also induce autophagy, possibly through mTOR4. Further studies are necessary to examine the involvement of 
mTOR in autophagy induction by other natural polyphenols. Inhibition of mTOR has been shown to be a good 
strategy in the treatment of various illnesses, such as cancer, neurodegenerative diseases, and diabetes41. This 
study will provide a basis for the identification of unknown mTOR-based effects of resveratrol.
Methods
Cell culture. GFP_LC3 HeLa was generated as previously described42. The above-mentioned cells and 
HEK293 cells were maintained with DMEM (Dulbecco’s modified Eagle’s medium) complemented with 10% fetal 
bovine serum (FBS, Lonza). To measure mTOR activity upon resveratrol treatment, cells were pretreated with 50 
μ M resveratrol (Sigma-Aldrich) for 30 min before stimulation with insulin or amino acids. Amino acid or serum 
fasting was conducted by maintaining cells with HBSS (Hank’s balanced salt solution; Invitrogen) supplemented 
with 10% dialyzed FBS (Invitrogen) or DMEM only, respectively. Before the resveratrol treatment, 10 μ M H-89 
(Biomol) was add for 1 h. For autophagy formation analysis using Western blotting, 10 μ M of resveratrol was 
treated into cells in the presence or absence of 10 μ M of Bafilomycin A1 (Enzo) for 2 h and cells were subjected to 
SDS-PAGE and Western blotting.
MTT assay. Cells were seeded onto 96-well plates, which were placed in an incubator overnight to allow for 
attachment and recovery. In brief, cells were treated with 100 μ M resveratrol for 48 h and MTT was then dissolved 
to a concentration of 5 mg/ml in warm assay medium. A total of 20 μ l MTT solution was transferred to each 
well to yield a final volume of 120 μ l/well. Plates were incubated for 4 h at 37 °C in 5% CO2. Following incuba-
tion, supernatants were removed and 100 μ l DMSO was added. Dissolved precipitates were measured with plated 
reader with wavelength at 540 nm.
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In vitro kinase assay and analysis of enzyme kinetics. mTORC1 kinase assay was performed as 
described previously, with some modifications43. Briefly, immunoprecipitated HA-mTOR (kindly provided by 
Dr. Sabaini, MIT) was washed three times and incubated with kinase assay buffer (20 mM HEPES, 50 mM KCl, 
10 mM MgCl2), 200 ng of 4E-BP1 (Stratagene) and the indicated amount of resveratrol for 10 min on ice. The 
reaction was started with the addition of 50 or 100 μ M ATP and was conducted at 30 °C for 10 min. The reaction 
was stopped by the addition of 5x sample buffer. For a kinase assay using recombinant mTOR, GST-mTOR (Life 
Technologies) was used and GST-S6K, which is generated by PCR amplification of kinase dead fragment S6K 
(322 to C-term) and subcloning into pGEX-4T1 vector was purified from E.coli and used as a substrate. An inn-
hibitory curve was drawn using Sigma Plot.
Immunoprecipitation and Western blotting. HA-mTOR cDNA, HA-Raptor cDNA (kindly provided 
by Dr. Sabaini, MIT), FLAG-mTOR cDNA (insertion of PCR product from HA-mTOR cDNA into pCMV vec-
tor) and FLAG-D2195A mTOR (generated by site directed mutagensis) were transfected with Lipofectamine 
(Invitrogen) according to the manufacturer’s instructions. Cells were lysed in buffer containing 40 mM HEPES, 
120 mM NaCl, 50 mM NaF, 10 mM β -glycerophosphate, 1 mM EDTA, 10 mM sodium pyrophosphate, 1 mM 
PMSF, 1 μ g/μ l aprotinin, 2 μ g/μ l leupeptin and 0.3% CHAPS. Except for the IP samples, 1% TX-100 was used as 
a detergent. Then 700–1000 μ g of protein was incubated with the respective antibody for 4 h followed by incu-
bation with protein A-conjugated agarose beads. Antibody immobilized beads (Sigma-Aldrich) were used for 
FLAG-mTOR. Beads were washed three times with the lysis buffer and resuspended with the sample buffer. 
Prepared samples were subjected to SDS-PAGE (6–16% gradient) and transferred to NC membranes (Amersham 
Biosciences). The membranes were blocked with TTBS buffer containing 5% skim milk and incubated over-
night at 4 °C with antibodies against ULK1 (Santa Cruz Biotechnology), Rictor (Bethyl Laboratories), actin 
(MP Biomedicals) and other proteins (Cell Signaling). The membranes were next washed with TTBS, incu-
bated with HRP-conjugated secondary antibodies at room temperature for 1 h, and washed again with TTBS. 
Antibody-bound membranes were developed using ECL (Thermo Fisher).
Microscopic analysis of autophagy formation. On day 1, HeLa cells stably expressing GFP_LC3 
(kindly provided by Dr. Yu Li, Tsinghua University) were plated onto poly-lysine coated glass coverslips. On day 
2, medium was changed with fresh medium containing DMSO or resveratrol at the indicated concentration for 
2 h. The medium was then aspirated and cells were washed twice with PBS. Cells were fixed with 4% formaldehyde 
for 10 min at RT and stained with DAPI for 5 min at RT. Washing three times with PBS was conducted between 
each step. The coverslips were mounted on a slide glass and visualized using confocal microscopy (Carl Zeiss), 
and randomly captured images from various fields were used for autophagy formation analysis. GFP punctate 
positive cells were quantified as autophagy induced cells. The total number of cells was determined by measuring 
DAPI-positive cells.
Lentiviral preparation and viral infection. Lentiviral shRNAs were prepared and transduced according 
to the Addgene protocol. Briefly, the pLKO empty vector or pLKO shULK1_8 (purchased from Addgene) was 
transfected with pMD2.G and psPAX2 (purchased from Addgene) using Lipofectamine according to the manu-
facturer’s instructions(Invitrogen). Media were collected at 24 h and 48 h after transfection. Collected media were 
centrifuged at 1200 rpm for 5 min and filtered with 0.45-μ m filter. For virus infection, virus-containing media 
were diluted with growth medium and added to plated cells. Twenty-four hours after infection, the medium was 
replaced with fresh medium. Twenty-four hours after changing the medium, infected cells were used for the var-
ious experiments based on experimental purpose.
Computational docking simulation. Three dimensional (3D) atomic coordinates were prepared from the 
X-ray crystal structure of mTOR in complex with the potent inhibitor, Torin2 (PDB code: 4JSX)1 as the receptor 
for docking simulations with resveratrol. Gasteiger-Marsilli atomic charges2 were assigned for all protein and 
ligand atoms to calculate the electrostatic interaction in the mTOR-resveratrol complex44. Docking simulations 
were then conducted with the AutoDock program3 to obtain the binding mode of resveratrol with respect to 
mTOR45. Of the 20 conformations of resveratrol generated in docking simulations, those clustered together have 
similar binding modes differing by less than 1.5 Å in positional root-mean-square deviation. The most stable 
binding configuration in the top-ranked cluster was selected for further analysis.
Statistical Analyses. Microsoft Excel was used for statistical analysis. Data are presented as means ± SEM. 
Comparisons between two groups were made by unpaired two-tailed Student’s t-tests. p values < 0.05 were con-
sidered statistically significant.
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